Fuso Pharmaceutical Industries,Ltd. has executed a design and construction contract with CXO for the Okayama No.2 Plant. A multi-story automated warehouse will be added within the Okayama site and a powder dialysis agent line will be newly installed, with oral formulation production sites relocated and consolidated. Total investment approx. 140 hundred million yen, construction start 2026\/12, completion 2028\/3, production commencement 2028\/12. No change to the earnings forecast for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fuso Pharmaceutical Industries,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4538-20260930-01.pdf","jir_short_summary":"Fuso Pharmaceutical Industries,Ltd. has executed a design and construction contract with CXO for the Okayama No.2 Plant. A multi-story automated warehouse will be added within the Okayama site and a powder dialysis agent line will be newly installed, with oral formulation production sites relocated and consolidated. Total investment approx. 140 hundred million yen, construction start 2026\/12, completion 2028\/3, production commencement 2028\/12. No change to the earnings forecast for the fiscal year ending March 2027.","jir_summary":"### Overview of Business Update\nThis notice concerns the execution of a design and construction contract for the Okayama No.2 Plant. To strengthen the functions of the Okayama No.1 Plant, a powder dialysis agent line will be newly installed and production sites will be reorganized and consolidated to enhance BCP and improve productivity. CXO is a comprehensive engineering company with achievements in the life sciences field and will be responsible for design through construction.\n\n### Investment Scale and Schedule\nThe name of the facility is Okayama No.2 Plant, located at 9033 Satomi, Satosho-cho, Asakuchi-gun, Okayama Prefecture. The building is a five-story steel-frame structure with a total floor area of approximately 8,800 square meters. Total investment approx. 140 hundred million yen. Contract execution date 2026\/9\/30, planned construction start December 2026, planned completion March 2028, planned production start December 2028.","jir_financial_highlights":"Total investment: 140 hundred million yen (Unknown)\nPlanned construction start: December 2026 (Unknown)\nPlanned completion: March 2028 (Unknown)\nPlanned production start: December 2028 (Unknown)","jir_category":"","jir_hashtags":"#FusoPharmaceuticalIndustries, #BusinessUpdate, #CapitalExpenditure, #OkayamaNo2Plant","jir_key_figures":"Total investment: 140 hundred million yen\nPlanned construction start: December 2026\nPlanned completion: March 2028\nPlanned production start: December 2028","jir_meta_title":"Fuso Pharmaceutical Industries,Ltd. Announces Execution of Design and Construction Contract for Okayama No.2 Plant | September 2026","jir_meta_description":"Fuso Pharmaceutical Industries,Ltd. has executed a design and construction contract with CXO for the Okayama No.2 Plant. Total investment approx. 140 hundred million yen; construction starts December 2026, completion March 2028, production begins December 2028.","jir_og_title":"Fuso Pharmaceutical Industries,Ltd. Executes Design and Construction Contract for Okayama No.2 Plant | September 2026","jir_og_description":"Executed a design and construction contract with CXO for the Okayama No.2 Plant. New powder dialysis agent line and consolidation of domestic production sites to improve productivity. Investment approx. 140 hundred million yen; construction starts December 2026, completion March 2028, production begins December 2028.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-125028","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n